Farmas USA

Ya la seguía,,,,estoy con la caja en mínimos:((
Haber si mañana podemos salir de alguna...

Menuda cabra loca esta HZNP ... con el juego que tiene de irse con el MACD a rojo para luego girarse de repente ... a mi de esas me va a dejar fuera todas. Asi que cambiaré de estrategia para la proxima vez.

SGYP

Grafico semanal para ver perspectiva + detalle en diario.

La proyeccion maxima del HCH era hasta los 1,2x ... RSI diario en 22 ... bastante sobrevendida. Esperemos que eso ayude.

ARNA

Arena Investors Need To Pay Attention To Celgene And Ozanimod

Arena's Etrasimod is seen as a competitor to Ozanimod.

Celgene acquired Ozanimod in a $7.2 billion deal.

Ozanimod may have issues that will delay its development.  This could be good for Arena.

https://seekingalpha.com/article/4168362-arena-investors-need-pay-attention-celgene-ozanimod?app=1&auth_param=7ib4d:1deik47:30302e463fd3b0d33dfeedcfc882cabd&uprof=44

NovoNordisk ha sacado buenos números... en Europa sube fuerte (+6.7%).

NVO

KERX

Resignation of the company’s CEO/President and Board member que los analistas ven con malos ojos

Y venta insider ridícula:

http://insideri.com/1537670_000111422018000047_0001114220-18-000047

Regulus launches early-stage study of RGLS4326 in inherited kidney cyst disorder; shares up 3%

May 1, 2018 11:38 AM ET|About:  Regulus Therapeutics (RGLS)|By:  Douglas W. House, SA News Editor 

Regulus Therapeutics ( RGLS +3%)  initiates a Phase 1 multiple ascending dose clinical trial assessing RGLS4326 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), an inherited disorder characterized by the formation of cysts on the kidney that leads to failure.

The company says RGLS4326 is an oligonucleotide designed to inhibit a microRNA cluster called  miR-17 that plays a key role in a range of development processes, immune, cardiovascular and neurodegenerative diseases and aging.

ADPKD is caused by mutations in the PKD1 and PKD2 genes which code for the proteins  polycystin-1 and polycystin-2, respectively. Both play key roles in kidney cell development.

ACAD

Fuera los otros 300 cromos a 17.10  total las 2 ventas, unos +650$

Si se ponen a tiro,, miraremos de entrar,, hasta el 7/5  :))))

ACAD

Dentro otra vez, 300 cromos a 16.85